Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia

The study addresses the challenge of developing topical androgen receptor (AR) antagonists for androgenetic alopecia (AGA) that are both effective and have low systemic toxicity. The first-generation AR antagonist, 14-P1, showed good safety and pharmacokinetics but required high doses due to suboptimal AR antagonism. Through structural optimization and a dual soft drug design strategy, the researchers developed a new candidate, 39, which demonstrated strong AR antagonism with an IC50 of 20.6 ± 2.3 nM and favorable pharmacokinetic profiles. In a hair-growth mouse model, 0.5% of compound 39 showed similar efficacy to 0.5% pyrilutamide but with faster response times (14 days compared to 21 days) while maintaining safety. This approach successfully combines therapeutic effectiveness with reduced systemic toxicity, offering a promising direction for future topical AR antagonist development.